8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 14, 2010

BIOMET, INC.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

Indiana	001-15601	35-1418342
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

56 East Bell Drive

Warsaw, Indiana 46582

(Address of Principal Executive Offices, Including Zip Code)

(574) 267-6639

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. (Results of Operations and Financial Condition)

On April 14, 2010, the Company issued a press release with respect to results for the third fiscal quarter of fiscal 2010. The press release attached hereto as Exhibit 99.1 is incorporated by reference herein.

The earnings release attached as Exhibit 99.1 includes non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP. Management exercises judgment in determining which types of charges or other items should be excluded from non-GAAP measures. Management uses this non-GAAP information internally to evaluate the performance of the core operations, establish operational goals and forecasts that are used in allocating resources and to evaluate the Company’s performance period over period. Additionally, Biomet’s management is evaluated on the basis of some of these non-GAAP financial measures when determining achievement of their incentive compensation performance targets. The Company believes that its disclosure of these non-GAAP financial measures provides investors greater transparency to the information used by Biomet management for its financial and operational decision-making and enables investors to better understand the Company’s period-to-period operating performance.

The non-GAAP financial measures included in the press release consist of net sales excluding the impact of foreign currency (constant currency), net sales excluding dental sales, operating income as adjusted, net income as adjusted, free cash flow, unlevered free cash flow, net debt, Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), Adjusted EBITDA (as defined by our bank agreement, the method to calculate this is likely to be different from methods used by other companies), gross profit as adjusted, selling, general and administrative expense as adjusted, and research and development expense as adjusted. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are included elsewhere in the press release.

The term “as adjusted,” a non-GAAP financial measure, refers to financial performance measures that exclude certain income statement line items, such as interest, taxes, depreciation or amortization and/or exclude certain expenses as defined by our bank agreement, such as restructuring charges, non-cash impairment charges, integration and facilities opening costs or other business optimization expenses, new systems design and implementation costs, certain start-up costs and costs related to consolidation of facilities, certain non-cash charges, advisory fees paid to the private equity owners, certain severance charges, purchase accounting costs, stock-based compensation and payments, payments to distributors that are not in the ordinary course of business, litigation costs, and other related charges.

The following is an explanation of each of the items, as defined by our bank agreement, that management excluded from one or more of the non-GAAP financial measures used in this press release and the reasons for excluding each of these items:

Impact of Foreign Currency. The Company excludes the foreign currency impact on net sales information compared to prior year results primarily because it is not reflective of the ongoing operating results and is not used by management in evaluation of net sales performance. The Company further believes this information is useful to investors in that it provides period over period comparability. The impact of foreign currency exchange rates is calculated by translating actual current period net sales at the prior year exchange rate. These results are used to determine year-over-year percentage increase or decrease that excludes the impact of changes in foreign currency exchange rates.

Purchase Accounting Depreciation and Amortization. Depreciation and amortization related to the Merger are excluded in non-GAAP measures as they are not reflective of the Company’s ongoing operational performance or liquidity. The Company further believes the exclusion of this information in the applicable non-GAAP financial measure is useful to investors in that it provides period over period comparability.

Goodwill and Intangible Asset Impairment Charge. During fiscal 2009, the Company recorded a $551.1 million goodwill and definite and indefinite-lived intangible asset impairment charge associated with the dental reconstructive business unit. The Company excludes this from non-GAAP measures because it is not reflective of the Company’s ongoing operational performance or liquidity. The Company further believes the exclusion of this information in the applicable non-GAAP financial measure is useful to investors in that it provides period over period comparability.

Share-Based Payment. Stock-based compensation expense is excluded from non-GAAP measures primarily because they are non-cash expenses. The Company further believes that excluding this item is useful to investors in that it facilitates comparisons to competitors’ operating results.

Distributor Agreements. Payments to distributors that are not in the ordinary course of business are excluded in non-GAAP measures as they are not reflective of the Company’s ongoing operational performance. The Company further believes the exclusion of this information in the applicable non-GAAP financial measure is useful to investors in that it provides period over period comparability.

Litigation Settlements and Reserves and Other Legal Fees. The Company excludes litigation related expenses from non-GAAP measures that are not reflective of the Company’s ongoing operational performance. The Company further believes this information is useful to investors in that it provides period over period comparability.

Operational Restructuring and Consulting Expenses Related to Operational Improvement Initiatives. Restructuring charges relate principally to employee severance and facility consolidation costs resulting from the closure of facilities and other workforce reductions attributable to our efforts to reduce costs. The Company excludes these costs from non-GAAP measures primarily because it is not reflective of the ongoing operating results and they are not used by management to assess ongoing operational performance. The Company further believes the exclusion of this information in the applicable non-GAAP financial measure is useful to investors in that it provides period over period comparability.

Sponsor Fee. Upon completion of the Merger, the Company entered into a management services agreement with certain affiliates of the Sponsors, pursuant to which such affiliates of the Sponsors or their successors assigns, affiliates, officers, employees, and/or representatives and third parties (collectively, the “Managers”) provide management, advisory, and consulting services to the Company. Pursuant to such agreement, the Managers received a transaction fee equal to 1% of total enterprise value of the Transactions for the services rendered by such entities related to the Transactions upon entering into the agreement, and the Sponsors receive an annual monitoring fee equal to 1% of the Company’s annual Adjusted EBITDA (as defined in our bank agreement) as compensation for the services rendered and reimbursement for out-of-pocket expenses incurred by the Managers in connection with the agreement and the Transactions. The Company excludes these costs from non-GAAP measures primarily because it is not reflective of the ongoing operating results and they are not used by management to assess ongoing operational performance. The Company further believes the exclusion of this information in the applicable non-GAAP financial measure is useful to investors in that it provides period over period comparability.

Other. Other relates primarily to costs incurred shortly after the Merger that management considers not in the ordinary course of business. The Company excludes these costs from non-GAAP measures primarily because it is not reflective of the ongoing operating results, are excluded from adjusted EBITDA as defined by our bank agreement, and they are not used by management to assess ongoing operational performance. The Company further believes the exclusion of this information in the applicable non-GAAP financial measure is useful to investors in that it provides period over period comparability.

The following is an explanation of each of the items that management excluded from one or more of the non-GAAP financial measures used in this press release and the reasons for excluding each of these items:

Impact of Dental. Unfavorable conditions in the economy have had an adverse effect on the Company’s dental business during fiscal 2010 and fiscal 2009 principally due to the elective nature of dental implant procedures, which are typically not reimbursed by private insurance plans or governmental agencies. Net dental sales are excluded from reconstructive net sales and total net sales to provide management and investors better insight into the performance of the core reconstructive business.

Tax Effect on Special and Purchase Accounting Items. This amount is used to present the impact of the above non-GAAP adjustments on net income, as adjusted.

Net Debt. Net debt is the sum of the Company’s total debt less cash and cash equivalents and short-term investments. The Company believes net debt provides a useful measure of the Company’s liquidity and overall debt position.

The Company is furnishing the information contained in this report, including the Exhibit, pursuant to Item 2.02 of Form 8-K promulgated by the Securities and Exchange Commission (the “SEC”). This information shall not be deemed to be “filed” with the SEC or incorporated by reference into any other filing with the SEC.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.	Document
99.1	Press Release issued April 14, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 14, 2010

BIOMET, INC.
/s/ Bradley J. Tandy
By:	Bradley J. Tandy
Its:	Senior Vice President, General Counsel and Secretary

EX-99.1

Exhibit 99.1

BIOMET ANNOUNCES FINANCIAL RESULTS FOR THIRD QUARTER OF FISCAL YEAR 2010

WARSAW, Ind., April 14, 2010 – Biomet, Inc. announced today financial results for its third fiscal quarter ended February 28, 2010.

• Net sales increased 9% (6% constant currency) to $670 million worldwide, with 6% growth in the U.S.

• Reconstructive sales, excluding dental, increased 13% (10% constant currency) worldwide, with U.S. growth of 11%

• Knee sales increased 17% (13% constant currency) worldwide and increased 13% in the U.S.

• Reported net loss of $3 million improved from a net loss of $479 million for the third quarter of fiscal year 2009

• Adjusted net income increased 53% to $67 million compared to $44 million for the third quarter of fiscal year 2009

• Adjusted EBITDA increased 9% to $251 million, or 37.4% of net sales

Net sales increased 9% to $669.8 million during the third fiscal quarter ended February 28, 2010 from $615.0 million during the third quarter of fiscal year 2009. Excluding the effect of foreign currency, net sales increased 6% during the third quarter of fiscal year 2010.

U.S. sales increased 6% during the third quarter to $412.6 million; Europe sales increased 8% (flat at constant currency) to $181.4 million; and International (primarily Canada, South America, Mexico and the Pacific Rim) sales increased 28% (16% constant currency) to $75.8 million. Excluding dental and the impact of foreign currency, net sales during the third quarter increased 6% worldwide, 7% in the U.S., 2% in Europe, and 17% for International.

Reported operating income totaled $100.1 million during the third quarter of fiscal year 2010 compared to an operating loss during the third quarter of fiscal 2009 of $378.1 million, which included a $448.5 million impairment charge related to the goodwill and intangibles associated with our dental reconstructive business. Excluding special items, which included stock compensation expense in both periods, adjusted operating income for the third quarter increased 8% to $210.1 million, or 31.4% of net sales, compared to adjusted operating income of $193.9 million for the third quarter of fiscal year 2009.

On a reported basis, the Company recorded a net loss of $3.1 million during the third quarter of fiscal 2010 compared to a net loss of $478.7 million during the third quarter of fiscal 2009. Excluding special items, which included stock compensation expense in both periods and the impairment charge in the prior year, adjusted net income totaled $67.3 million during the third quarter of fiscal 2010 compared to adjusted net income of $44.1 million during the third quarter of fiscal year 2009.

Interest expense was $128.0 million during the third quarter compared to $132.3 million during the third quarter of fiscal year 2009, primarily due to lower interest rates on floating rate debt.

Special items (pre-tax) totaled $110.0 million during the third quarter of fiscal 2010 and included $95.6 million of non-cash amortization and depreciation expense related to the merger. Of the $14.4 million of non-merger related special items recorded during the third quarter, $4.8 million was stock compensation expense. A reconciliation of reported results to adjusted results is included in this press release, which is also posted on Biomet’s website: www.biomet.com

Excluding special items that included stock compensation expense in both periods, adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”) for the third quarter of fiscal 2010 increased 9% to $250.7 million, or 37.4% of net sales, compared to adjusted EBITDA of $229.8 million during the third quarter of fiscal year 2009.

Free cash flow (operating cash flow minus capital expenditures) for the third quarter totaled $131.0 million compared to free cash flow of $114.3 million for the third quarter of fiscal year 2009. Unlevered free cash flow (cash flow before debt service) for the third quarter was $192.1 million compared to unlevered free cash flow for the same period last fiscal year of $171.7 million.

The Company’s reported net debt balance at February 28, 2010, was $5.855 billion with cash on hand of $167 million. From the transaction closing date of September 25, 2007, to the quarter ended February 28, 2010, reported net debt decreased by $298 million due to debt repayments of $190 million, an increase in cash of $94 million, and a $14 million decrease due to favorable foreign currency translation on the Company’s Euro denominated debt since the transaction closing date.

At February 28, 2010, the Company’s senior secured leverage ratio was 3.43 times the last twelve month’s (“LTM”) adjusted EBITDA (including run rate cost savings as defined in the Company’s Credit Agreement dated September 25, 2007), compared to 4.7 times at the merger date. At the end of the third quarter of fiscal year 2010, the net debt leverage ratio was 5.81 times LTM adjusted EBITDA (including run rate cost savings) compared to 7.7 times at the merger date.

P.O. Box 587 Ÿ Warsaw, IN 46581-0587 Ÿ Office: 574.267.6639 Ÿ www.biomet.com

Biomet’s President and Chief Executive Officer Jeffrey R. Binder remarked, “Strong market demand for Biomet’s orthopaedic reconstructive products continued to drive the Company’s sales growth during the third quarter, most notably in our knee and extremity product categories. On a constant currency basis, knee sales increased 13% worldwide, while global extremity sales grew 27%. Additionally, we recorded very strong sales growth from our international division, as we continued to successfully penetrate key markets during the quarter.”

	Third Quarter Sales Performance
	Worldwide Reported Quarter 3 - 2010		Worldwide Reported Growth %		Worldwide CC Growth %		United States Growth %
Reconstructive	$	508.4	12	%	8	%	10	%
Hips			8	%	4	%	3	%
Knees			17	%	13	%	13	%
Dental			3	%	-1	%	1	%
Extremities			31	%	27	%	45	%
Other			6	%	2	%	5	%
Fixation		58.4	2	%	0	%	-3	%
Spine		56.1	4	%	4	%	3	%
Other		46.9	-7	%	-9	%	-7	%
Total Sales	$	669.8	9	%	6	%	6	%

During the third quarter of fiscal year 2010, Biomet’s knee sales increased 13% worldwide on a constant currency basis and grew 13% in the U.S. Key products that continued to drive the strong knee sales growth included the primary and revision components of the Vanguard^® Complete Knee System, E1™ Antioxidant Infused Tibial Bearings, the Signature™ Personalized Patient Care program, and Regenerex^® Primary Tibial Trays.

Excluding the impact of currency, global hip sales increased 4% during the third quarter, with domestic sales growth of 3%. In the U.S., the fiscal 2010 third quarter hip sales were up against a strong growth rate from the third quarter of fiscal 2009 of 16%. Advanced technologies contributing to third quarter sales growth were E1™ Antioxidant Infused Bearings, Regenerex^® Ringloc^®+ Cups and Biolox delta^™1 Ceramic Femoral Heads, as well as Taperloc^® Microplasty^® Hip Stems. In Europe, the Exceed ABT™ Advanced Bearing Technologies System² continued to receive strong market demand during the third quarter, driven primarily by its ceramic-on-ceramic and E1™ Antioxidant Infused Bearing options.

The Company’s extremity sales increased 27% worldwide at constant currency and increased 45% in the U.S., as a result of excellent market demand for the Comprehensive^® Primary, Reverse, and Fracture Shoulder Systems, the Discovery^® Elbow and the ExploR^® Modular Radial Head. Strong demand for the anatomical and reverse versions of the T.E.S.S. Shoulder System³ contributed to extremity sales in Europe.

Excluding the effect of currency, dental reconstructive device sales decreased 1% during the third quarter of fiscal 2010, while sales in the U.S. increased 1%. During the third quarter, dental reconstructive device sales continued to be impacted by pressure on the dental implant market due to the global economic climate, but to a lesser extent than the prior few quarters. The Encode^® Complete System continued to receive favorable market acceptance worldwide during the quarter.

Fixation sales were flat worldwide on a constant currency basis during the third quarter and decreased 3% in the U.S. Double-digit growth for craniomaxillofacial fixation sales and the positive sales growth for internal fixation were offset by decreased sales of external fixation and electrical stimulation devices. The TraumaOne™ Fixation System continued to penetrate the craniomaxillofacial fixation market during the third quarter, while the OptiLock^® Proximal Humeral Plating System was the key contributor to internal fixation sales growth.

During the third quarter, spine sales increased 4% worldwide at constant currency and increased 3% in the U.S. Sales growth in the spine hardware and orthobiologics product category was impacted by a slight decrease in spinal stimulation sales. Key spine products during the third quarter included the Solitaire™ PEEK Anterior Spine System, the C-Thru™ Small Stature PEEK-OPTIMA^®4 Spacer, the ESL^® PEEK-OPTIMA^®4 Posterior Spacer, the Polaris™ Deformity System and the MaxAn™ Anterior Cervical Plate System⁵; as well as the Synergy™ Spinal System in Europe.

Sales of “other” products decreased 9% worldwide at constant currency during the third quarter and decreased 7% in the U.S. High single-digit sales growth for sports medicine products was more than offset by decreased sales of softgoods and bracing products. Sports medicine products that contributed to sales growth during the quarter were the ToggleLoc™ Femoral Fixation Device with ZipLoop™ Technology, the ZipTight™ Fixation System, the ComposiTCP™ Interference Screw and the MicroMax™ Flex Suture Anchor.

¹ Biolox delta™ is a trademark of CeramTec AG.

² The Exceed ABT™ Advanced Bearing Technologies System is not available for sale in the United States.

³ The T.E.S.S. Shoulder System is not available for sale in the United States.

⁴ PEEK-OPTIMA^® is a registered trademark of Invibio^® Biomaterial Solutions.

⁵ The MaxAn^™ Anterior Cervical Plate System incorporates technology developed by Gary K. Michelson, M.D.

All trademarks herein are the property of Biomet, Inc. or its subsidiaries unless otherwise indicated.

Financial Schedule Presentation

The Company’s unaudited condensed consolidated financial statements as of and for the three and nine months ended February 28, 2010 and 2009 and other financial data included in this press release have been prepared in a manner that complies, in all material respects, with generally accepted accounting principles in the United States (except with respect to certain non-GAAP financial measures discussed below) and reflects purchase accounting adjustments related to the merger referenced below.

About Biomet

Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. Biomet’s product portfolio encompasses reconstructive products, including orthopedic joint replacement devices, bone cements and accessories, autologous therapies and dental reconstructive implants; fixation products, including electrical bone growth stimulators, internal and external orthopedic fixation devices, craniomaxillofacial implants and bone substitute materials; spinal products, including spinal stimulation devices, spinal hardware and orthobiologics; and other products, such as arthroscopy products and softgoods and bracing products. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in approximately 90 countries.

The Merger

Biomet Inc. finalized the merger with LVB Acquisition Merger Sub, Inc., a wholly-owned subsidiary of LVB Acquisition, Inc., on September 25, 2007, which we refer to in this press release as the “merger date.” LVB Acquisition, Inc. is indirectly owned by investment partnerships directly or indirectly advised or managed by The Blackstone Group, Goldman Sachs & Co., Kohlberg Kravis Roberts & Co. and TPG Capital.

Contacts

For further information contact Daniel P. Florin, Senior Vice President and Chief Financial Officer at (574) 372-1687 or Barbara Goslee, Director, Corporate Communications at (574) 372-1514.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Those statements are often indicated by the use of words such as “will,” “intend,” “anticipate,” “estimate,” “expect,” “plan” and similar expressions. Forward-looking statements involve certain risks and uncertainties. Actual results may differ materially from those contemplated by the forward looking statements due to, among others, the following factors: the success of the Company’s principal product lines; the results of ongoing investigations by the United States Department of Justice and the United States Securities and Exchange Commission; the ability to successfully implement new technologies; the Company’s ability to sustain sales and earnings growth; the Company’s success in achieving timely approval or clearance of its products with domestic and foreign regulatory entities; the impact to the business as a result of compliance with federal, state and foreign governmental regulations and with the Corporate Integrity Agreement; the impact to the business as a result of the economic downturn in both foreign and domestic markets; the impact of federal health care reform; the impact of anticipated changes in the musculoskeletal industry and the ability of the Company to react to and capitalize on those changes; the ability of the Company to successfully implement its desired organizational changes and cost-saving initiatives; the impact to the business as a result of the Company’s significant international operations, including, among others, with respect to foreign currency fluctuations and the success of the Company’s transition of certain manufacturing operations to China; the impact of the Company’s managerial changes; the ability of the Company’s customers to receive adequate levels of reimbursement from third-party payors; the Company’s ability to maintain its existing intellectual property rights and obtain future intellectual property rights; the impact to the business as a result of cost containment efforts of group purchasing organizations; the Company’s ability to retain existing independent sales agents for its products; and other factors set forth in the Company’s filings with the SEC, including the Company’s most recent annual report on Form 10-K and quarterly reports on Form 10-Q. Although the Company believes that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or non-occurrence of future events. There can be no assurance as to the accuracy of forward-looking statements contained in this press release. The inclusion of a forward-looking statement herein should not be regarded as a representation by the Company that the Company’s objectives will be achieved. The Company undertakes no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements which speak only as of the date on which they were made.

*Non-GAAP Financial Measures:

Management uses non-GAAP financial measures, such as net sales excluding dental sales and/or the impact of foreign currency (constant currency), operating income as adjusted, net income as adjusted, free cash flow, unlevered free cash flow, net debt, Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), Adjusted EBITDA (as defined by our bank agreement, the method to calculate this is likely to be different from methods used by other companies), gross profit as adjusted, selling, general and administrative expense as adjusted, and research and development expense as adjusted. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are included elsewhere in this press release.

The term “as adjusted,” a non-GAAP financial measure, refers to financial performance measures that exclude certain income statement line items, such as interest, taxes, depreciation or amortization and/or exclude certain expenses as defined by our bank agreement, such as restructuring charges, non-cash impairment charges, integration and facilities opening costs or other business optimization expenses, new systems design and implementation costs, certain start-up costs and costs related to consolidation of facilities, certain non-cash charges, advisory fees paid to the private equity owners, certain severance charges, purchase accounting costs, stock-based compensation and payments, payments to distributors that are not in the ordinary course of business, litigation costs, and other related charges.

These non-GAAP measures are not in accordance with, or an alternative for, generally accepted accounting principles in the United States. Biomet management believes that these non-GAAP measures provide useful information to investors; however, this additional non-GAAP financial information is not meant to be considered in isolation or as a substitute for financial information prepared in accordance with GAAP.

Biomet, Inc.

Product Net Sales*

Three Month Period Ended February 28, 2010 and February 28, 2009

(in millions, unaudited)

	Three Months Ended February 28, 2010		Three Months Ended February 28, 2009		Reported Growth %		Constant Currency Growth %
Reconstructive	$	508.4	$	453.8	12	%	8	%
Fixation		58.4		57.0	2	%	—	%
Spine		56.1		53.8	4	%	4	%
Other		46.9		50.4	(7	)%	(9	)%
Total Sales	$	669.8	$	615.0	9	%	6	%

	2010 Net Sales Growth As Reported		Currency Impact		2010 Net Sales Growth in Local Currencies		Impact of Dental		2010 Net Sales Growth in Local Currencies Excluding Dental
Reconstructive	12	%	(4	)%	8	%	2	%	10	%
Hips	8	%	(4	)%	4	%
Knees	17	%	(4	)%	13	%
Extremities	31	%	(4	)%	27	%
Dental	3	%	(4	)%	(1	)%
Other	6	%	(4	)%	2	%
Fixation	2	%	(2	)%	—	%
Spine	4	%	—	%	4	%
Other	(7	)%	(2	)%	(9	)%
Total	9	%	(3	)%	6	%	—	%	6	%

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Product Net Sales*

Nine Month Period Ended February 28, 2010 and February 28, 2009

(in millions, unaudited)

	Nine Months Ended February 28, 2010		Nine Months Ended February 28, 2009		Reported Growth %		Constant Currency Growth %
Reconstructive	$	1,499.6	$	1,383.2	8	%	7	%
Fixation		175.3		175.5	—	%	(1	)%
Spine		174.2		160.4	9	%	9	%
Other		146.4		145.7	1	%	—	%
Total Sales	$	1,995.5	$	1,864.8	7	%	6	%

	2010 Net Sales Growth As Reported		Currency Impact		2010 Net Sales Growth in Local Currencies		Impact of Dental		2010 Net Sales Growth in Local Currencies Excluding Dental
Reconstructive	8	%	(1	)%	7	%	3	%	10	%
Hips	6	%	(1	)%	5	%
Knees	12	%	(1	)%	11	%
Extremities	26	%	—	%	26	%
Dental	(4	)%	(1	)%	(5	)%
Other	10	%	(1	)%	9	%
Fixation	—	%	(1	)%	(1	)%
Spine	9	%	—	%	9	%
Other	1	%	(1	)%	—	%
Total	7	%	(1	)%	6	%	2	%	8	%

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Geographic Segment Net Sales Percentage Summary*

Three Month Period Ended February 28, 2010 and February 28, 2009

(in millions, unaudited)

	Three Months Ended February 28, 2010		Three Months Ended February 28, 2009		Reported Growth %		Constant Currency Growth %
Geographic Segments:
United States	$	412.6	$	387.9	6	%	6	%
Europe		181.4		167.8	8	%	—	%
International		75.8		59.3	28	%	16	%
Total Sales	$	669.8	$	615.0	9	%	6	%

	2010 Net Sales Growth As Reported		Currency Impact		2010 Net Sales Growth in Local Currencies		Impact of Dental		2010 Net Sales Growth in Local Currencies Excluding Dental
United States	6	%	—	%	6	%	1	%	7	%
Europe	8	%	(8	)%	—	%	2	%	2	%
International	28	%	(12	)%	16	%	1	%	17	%
Total	9	%	(3	)%	6	%	—	%	6	%

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Geographic Segment Net Sales Percentage Summary*

Nine Month Period Ended February 28, 2010 and February 28, 2009

(in millions, unaudited)

	Nine Months Ended February 28, 2010		Nine Months Ended February 28, 2009		Reported Growth %		Constant Currency Growth %
Geographic Segments:
United States	$	1,220.9	$	1,135.9	7	%	7	%
Europe		542.4		532.6	2	%	1	%
International		232.2		196.3	18	%	13	%
Total Sales	$	1,995.5	$	1,864.8	7	%	6	%

	2010 Net Sales Growth As Reported		Currency Impact		2010 Net Sales Growth in Local Currencies		Impact of Dental		2010 Net Sales Growth in Local Currencies Excluding Dental
United States	7	%	—	%	7	%	1	%	8	%
Europe	2	%	(1	)%	1	%	3	%	4	%
International	18	%	(5	)%	13	%	(1	)%	12	%
Total	7	%	(1	)%	6	%	2	%	8	%

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

As Reported Consolidated Statements of Operations

(in millions, unaudited)

	Three Months Ended February 28, 2010			Three Months Ended February 28, 2009
Net sales	$	669.8		$	615.0
Cost of sales		194.7			186.1
Gross profit		475.1			428.9
Gross profit percentage		70.9	%		69.7	%
Selling, general and administrative		256.1			244.0
Research and development		26.6			20.0
Amortization		92.3			94.5
Goodwill and intangible assets impairment charge		—			448.5
Operating income (loss)		100.1			(378.1	)
Percentage of Sales		14.9	%		-61.5	%
Other expense (income), net		(4.0	)		9.7
Interest expense		128.0			132.3
Loss before income taxes		(23.9	)		(520.1	)
Income taxes		(20.8	)		(41.4	)
Tax rate		87.0	%		8.0	%
Net loss	$	(3.1	)	$	(478.7	)
Percentage of Sales		-0.5	%		-77.8	%

Biomet, Inc.

As Reported Consolidated Statements of Operations

(in millions, unaudited)

	Nine Months Ended February 28, 2010			Nine Months Ended February 28, 2009
Net sales	$	1,995.5		$	1,864.8
Cost of sales		593.6			562.5
Gross profit		1,401.9			1,302.3
Gross profit percentage		70.3	%		69.8	%
Selling, general and administrative		769.5			752.2
Research and development		76.7			66.9
Amortization		282.4			275.8
Goodwill and intangible assets impairment charge		—			448.5
Operating income (loss)		273.3			(241.1	)
Percentage of Sales		13.7	%		-12.9	%
Other expense (income), net		(18.9	)		30.3
Interest expense		389.6			412.6
Loss before income taxes		(97.4	)		(684.0	)
Income taxes		(64.3	)		(105.7	)
Tax rate		66.0	%		15.5	%
Net loss	$	(33.1	)	$	(578.3	)
Percentage of Sales		-1.7	%		-31.0	%

BIOMET, INC.

Other Financial Information

Operating Income, as reported to Operating Income, as adjusted

(in millions, unaudited)

	Three Months Ended February 28, 2010		Three Months Ended February 28, 2009
Operating income (loss), as reported	$	100.1	$	(378.1	)
Purchase accounting depreciation		4.4		4.4
Purchase accounting amortization		91.2		94.5
Goodwill and intangible assets impairment charge		—		448.5
Share-based payment		4.8		7.5
Litigation settlements and reserves and other legal fees		2.9		3.7
Operational restructuring		1.6		5.1
Consulting expenses related to operational improvement initiatives, and other related costs		2.5		3.6
Sponsor fee		2.6		2.2
Other		—		2.5
Operating income, as adjusted*	$	210.1	$	193.9

* See Non-GAAP Financial Measures Disclosure Above

BIOMET, INC.

Other Financial Information

Operating Income, as reported to Operating Income, as adjusted

(in millions, unaudited)

	Nine Months Ended February 28, 2010		Nine Months Ended February 28, 2009
Operating income (loss), as reported	$	273.3	$	(241.1	)
Purchase accounting depreciation		13.3		13.4
Purchase accounting amortization		279.4		275.8
Goodwill and intangible assets impairment charge		—		448.5
Share-based payment		14.3		26.3
Distributor agreements		—		2.0
Litigation settlements and reserves and other legal fees		8.1		18.7
Operational restructuring		16.3		9.9
Consulting expenses related to operational improvement initiatives, and other related costs		11.1		12.6
Sponsor fee		7.5		6.7
Other		—		4.1
Operating income, as adjusted*	$	623.3	$	576.9

* See Non-GAAP Financial Measures Disclosure Above

BIOMET, INC.

Other Financial Information

Net Loss to EBITDA, as reported

(in millions, unaudited)

	Three Months Ended February 28, 2010			Three Months Ended February 28, 2009
Net loss, as reported	$	(3.1	)	$	(478.7	)
Depreciation		43.9			40.3
Amortization		92.3			94.5
Interest expense		128.0			132.3
Other (income) expense, net		(4.0	)		9.7
Income taxes		(20.8	)		(41.4	)
EBITDA, as reported*	$	236.3		$	(243.3	)

* See Non-GAAP Financial Measures Disclosure Above

BIOMET, INC.

Other Financial Information

Net Loss to EBITDA, as reported

(in millions, unaudited)

	Nine Months Ended February 28, 2010			Nine Months Ended February 28, 2009
Net loss, as reported	$	(33.1	)	$	(578.3	)
Depreciation		133.4			120.4
Amortization		282.4			275.8
Interest expense		389.6			412.6
Other (income) expense, net		(18.9	)		30.3
Income taxes		(64.3	)		(105.7	)
EBITDA, as reported*	$	689.1		$	155.1

* See Non-GAAP Financial Measures Disclosure Above

BIOMET, INC.

Other Financial Information

EBITDA, as reported to EBITDA, as adjusted

(in millions, unaudited)

	Three Months Ended February 28, 2010		Three Months Ended February 28, 2009
Operating income (loss), as reported	$	100.1	$	(378.1	)
Depreciation		43.9		40.3
Amortization		92.3		94.5
EBITDA, as reported*	$	236.3	$	(243.3	)
Special items and purchase accounting adjustments:
Goodwill and intangible assets impairment charge		—		448.5
Share-based payment		4.8		7.5
Litigation settlements and reserves and other legal fees		2.9		3.7
Operational restructuring		1.6		5.1
Consulting expenses related to operational improvement initiatives, and other related costs		2.5		3.6
Sponsor fee		2.6		2.2
Other		—		2.5
EBITDA, as adjusted*	$	250.7	$	229.8

* See Non-GAAP Financial Measures Disclosure Above

BIOMET, INC.

Other Financial Information

EBITDA, as reported to EBITDA, as adjusted

(in millions, unaudited)

	Nine Months Ended February 28, 2010		Nine Months Ended February 28, 2009
Operating income (loss), as reported	$	273.3	$	(241.1	)
Depreciation		133.4		120.4
Amortization		282.4		275.8
EBITDA, as reported*	$	689.1	$	155.1
Special items and purchase accounting adjustments:
Goodwill and intangible assets impairment charge		—		448.5
Share-based payment		14.3		26.3
Distributor agreements		—		2.0
Litigation settlements and reserves and other legal fees		8.1		18.7
Operational restructuring		16.3		9.9
Consulting expenses related to operational improvement initiatives, and other related costs		11.1		12.6
Sponsor fee		7.5		6.7
Other		—		4.1
EBITDA, as adjusted*	$	746.4	$	683.9

* See Non-GAAP Financial Measures Disclosure Above

BIOMET, INC.

Reconciliation of GAAP Consolidated Net Loss to

Non-GAAP Adjusted Consolidated Net Income

(in millions, unaudited)

	Three Months Ended February 28, 2010			Three Months Ended February 28, 2009
Net loss, as reported	$	(3.1	)	$	(478.7	)
Purchase accounting depreciation		4.4			4.4
Purchase accounting amortization		91.2			94.5
Goodwill and intangible assets impairment charge		—			448.5
Share-based payment		4.8			7.5
Litigation settlements and reserves and other legal fees		2.9			3.7
Operational restructuring		1.6			5.1
Consulting expenses related to operational improvement initiatives, and other related costs		2.5			3.6
Sponsor fee		2.6			2.2
Other		—			2.5
Tax effect on special and purchase accounting items		(39.6	)		(49.2	)
Net income, as adjusted*	$	67.3		$	44.1

* See Non-GAAP Financial Measures Disclosure Above

BIOMET, INC.

Reconciliation of GAAP Consolidated Net Loss to

Non-GAAP Adjusted Consolidated Net Income

(in millions, unaudited)

	Nine Months Ended February 28, 2010			Nine Months Ended February 28, 2009
Net loss, as reported	$	(33.1	)	$	(578.3	)
Purchase accounting depreciation		13.3			13.4
Purchase accounting amortization		279.4			275.8
Goodwill and intangible assets impairment charge		—			448.5
Share-based payment		14.3			26.3
Distributor agreements		—			2.0
Litigation settlements and reserves and other legal fees		8.1			18.7
Operational restructuring		16.3			9.9
Consulting expenses related to operational improvement initiatives, and other related costs		11.1			12.6
Sponsor fee		7.5			6.7
Other		—			4.1
Tax effect on special and purchase accounting items		(125.6	)		(147.9	)
Net income, as adjusted*	$	191.3		$	91.8

* See Non-GAAP Financial Measures Disclosure Above

BIOMET, INC.

Other Financial Information

Senior Secured Leverage Ratio

(in millions, unaudited)

	February 28, 2010
Senior Secured Debt:
USD Term Loan B	$	2,287.3
EUR Term Loan B		1,166.2
Asset Based Revolver		—
Cash Flow Revolver		—
Consolidated Senior Secured Debt	$	3,453.5	A
Consolidated Total Debt	$	6,022.3	C
Cash		(167.4	)
Net Debt*	$	5,854.9	D
LTM EBITDA:*
Quarter 4 Fiscal 2009 EBITDA		242.5
Quarter 1 Fiscal 2010 EBITDA		230.3
Quarter 2 Fiscal 2010 EBITDA		265.4
Quarter 3 Fiscal 2010 EBITDA		250.7
“Run Rate” Cost Savings**		18.2
LTM EBITDA	$	1,007.1	B
Senior Secured Leverage Ratio		3.43	A /B
Total Leverage Ratio		5.98	C /B
Total Leverage Ratio (Net Debt)		5.81	D /B
Excluding Cost Savings		5.92

* See Non-GAAP Financial Measures Disclosure Above

** As defined by the Credit Agreement dated September 25, 2007

Biomet, Inc.

Balance Sheets

(in millions)

	(Unaudited) February 28, 2010		May 31, 2009
Assets
Cash and cash equivalents	$	167.4	$	215.6
Accounts receivable, net		522.7		511.1
Income tax receivable		16.7		20.0
Inventories		536.8		523.9
Current deferred income taxes		78.2		78.4
Prepaids and other current assets		46.1		39.1
Property, plant and equipment, net		650.0		636.1
Intangible assets, net		5,402.5		5,680.0
Goodwill		4,794.9		4,780.5
Other assets		107.1		116.2
Total Assets	$	12,322.4	$	12,600.9
Liabilities and Shareholder’s Equity
Current liabilities	$	540.8	$	550.0
Short-term borrowings		37.0		81.2
Long-term debt		5,985.3		6,131.5
Deferred income taxes, long-term		1,708.0		1,816.3
Other long-term liabilities		185.8		181.6
Shareholder’s equity		3,865.5		3,840.3
Total Liabilities and Shareholder’s Equity	$	12,322.4	$	12,600.9
Net Debt (a)*	$	5,854.9	$	5,997.1

(a) Net debt is the sum of total debt less cash and cash equivalents and short-term investments.

* See Non-GAAP Financial Measures Disclosure Above

Biomet, Inc.

Consolidated Statements of Cash Flows

(in millions, unaudited)

	Fiscal 2010
	Three Months Ended August 31, 2009			Three Months Ended November 30, 2009			Three Months Ended February 28, 2010			Nine Months Ended February 28, 2010
CASH FLOWS PROVIDED BY OPERATING ACTIVITIES:
Net loss	$	(22.8	)	$	(7.2	)	$	(3.1	)	$	(33.1	)
Adjustments to reconcile net loss to net cash from operating activities:
Depreciation and amortization		136.6			143.0			136.2			415.8
Amortization of deferred financing costs		2.8			2.8			2.9			8.5
Stock based compensation expense		5.2			4.3			4.8			14.3
Recovery for doubtful accounts receivable		(5.2	)		(0.6	)		(4.0	)		(9.8	)
Loss (gain) on sale of investments, net		(0.8	)		(0.4	)		(1.8	)		(3.0	)
Provision (recovery) for inventory obsolescence		6.5			2.3			(5.0	)		3.8
Deferred income taxes		(47.1	)		(30.7	)		(26.8	)		(104.6	)
Other		(1.1	)		6.2			4.0			9.1
Changes in operating assets and liabilities:
Accounts receivable		19.8			(47.5	)		13.9			(13.8	)
Inventories		(22.5	)		(9.4	)		(4.0	)		(35.9	)
Prepaid expenses		(4.4	)		(1.8	)		(1.2	)		(7.4	)
Accounts payable		(3.0	)		(6.1	)		(12.0	)		(21.1	)
Income tax receivable (payable)		14.6			8.3			(3.3	)		19.6
Accrued interest		70.0			(70.6	)		64.9			64.3
Other		(93.1	)		33.0			6.4			(53.7	)
Net cash provided by operating activities		55.5			25.6			171.9			253.0
CASH FLOWS USED IN INVESTING ACTIVITIES:
Proceeds from sales of investments		3.4			2.9			9.8			16.1
Purchases of investments		(1.8	)		(2.0	)		(9.5	)		(13.3	)
Net proceeds from sale of property and equipment		—			—			0.5			0.5
Capital expenditures		(53.9	)		(52.1	)		(40.9	)		(146.9	)
Acquisitions, net of cash acquired		(2.4	)		(6.6	)		(0.8	)		(9.8	)
Net cash used in investing activities		(54.7	)		(57.8	)		(40.9	)		(153.4	)
CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES:
Debt:
Proceeds under revolving credit agreements		20.1			—			0.2			20.3
Payments under revolving credit agreements		(1.3	)		(66.7	)		(0.4	)		(68.4	)
Payments under senior secured credit facility		(8.9	)		(9.0	)		(9.1	)		(27.0	)
Proceeds under asset-based revolver		—			—			(65.2	)		(65.2	)
Repurchases of senior notes		—			—			(8.7	)		(8.7	)
Equity:
Repurchase of common shares		(0.6	)		(0.5	)		(0.4	)		(1.5	)
Net cash provided by (used in) financing activities		9.3			(76.2	)		(83.6	)		(150.5	)
Effect of exchange rate changes on cash		0.7			(0.4	)		2.4			2.7
Increase (decrease) in cash and cash equivalents		10.8			(108.8	)		49.8			(48.2	)
Cash and cash equivalents, beginning of period		215.6			226.4			117.6			215.6
Cash and cash equivalents, end of period	$	226.4		$	117.6		$	167.4		$	167.4

Biomet, Inc.

Consolidated Statements of Cash Flows

(in millions, unaudited)

	Fiscal 2009
	Three Months Ended August 31,  2008			Three Months Ended November  30, 2008			Three Months Ended February 28, 2009			Nine Months Ended February 28, 2009
CASH FLOWS PROVIDED BY (USED IN) OPERATING ACTIVITIES:
Net loss	$	(59.9	)	$	(39.7	)	$	(478.7	)	$	(578.3	)
Adjustments to reconcile net loss to net cash from operating activities:
Depreciation and amortization		131.4			130.0			134.8			396.2
Amortization of deferred financing costs		2.8			2.9			2.8			8.5
Goodwill and intangible assets impairment charge		—			—			448.5			448.5
Stock based compensation expense		7.2			11.6			7.5			26.3
Provision (recovery) for doubtful accounts receivable		5.9			(9.4	)		(3.9	)		(7.4	)
Loss and impairment on investments, net		2.9			3.6			7.1			13.6
Provision (recovery) for inventory obsolescence		8.2			(7.8	)		0.5			0.9
Deferred income taxes		(31.6	)		(38.1	)		(76.3	)		(146.0	)
Other		0.7			(0.8	)		4.0			3.9
Changes in operating assets and liabilities:
Accounts receivable		(1.4	)		(39.1	)		(4.1	)		(44.6	)
Inventories		(26.6	)		1.1			2.8			(22.7	)
Prepaid expenses		6.0			(8.6	)		3.7			1.1
Accounts payable		(17.7	)		11.0			(0.2	)		(6.9	)
Income tax receivable (payable)		(8.2	)		2.5			58.1			52.4
Accrued interest		68.8			(69.6	)		60.1			59.3
Other		(22.6	)		32.1			(17.9	)		(8.4	)
Net cash provided by (used in) operating activities		65.9			(18.3	)		148.8			196.4
CASH FLOWS USED IN INVESTING ACTIVITIES:
Capital expenditures		(41.0	)		(51.9	)		(34.5	)		(127.4	)
Acquisitions, net of cash acquired		(2.0	)		(0.2	)		(7.3	)		(9.5	)
Net cash used in investing activities		(43.0	)		(52.1	)		(41.8	)		(136.9	)
CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES:
Debt:
Proceeds under revolving credit agreements		3.9			186.8			20.3			211.0
Payments under revolving credit agreements		(0.7	)		(16.1	)		(6.7	)		(23.5	)
Payments under senior secured credit facility		(9.3	)		(8.9	)		(8.7	)		(26.9	)
Equity:
Capital Contributions		0.2			1.7			1.8			3.7
Repurchase of common shares		(0.2	)		(0.4	)		(0.1	)		(0.7	)
Net cash provided by (used in) financing activities		(6.1	)		163.1			6.6			163.6
Effect of exchange rate changes on cash		(1.0	)		(6.8	)		(3.6	)		(11.4	)
Increase in cash and cash equivalents		15.8			85.9			110.0			211.7
Cash and cash equivalents, beginning of period		127.6			143.4			229.3			127.6
Cash and cash equivalents, end of period	$	143.4		$	229.3		$	339.3		$	339.3

BIOMET, INC.

Other Financial Information

GAAP Operating Cash Flow Reconciled to Free Cash Flow & Unlevered Free Cash Flow

(in millions, unaudited)

	Fiscal 2010
	Three Months Ended August 31, 2009			Three Months Ended November 30, 2009			Three Months Ended February 28, 2010			Nine Months Ended February 28, 2010
Net loss	$	(22.8	)	$	(7.2	)	$	(3.1	)	$	(33.1	)
Adjustments:
Depreciation and amortization		136.6			143.0			136.2			415.8
Amortization of deferred financing costs		2.8			2.8			2.9			8.5
Stock based compensation expense		5.2			4.3			4.8			14.3
Recovery for doubtful accounts receivable		(5.2	)		(0.6	)		(4.0	)		(9.8	)
Loss (gain) on sale of investments, net		(0.8	)		(0.4	)		(1.8	)		(3.0	)
Provision (recovery) for inventory obsolescence		6.5			2.3			(5.0	)		3.8
Deferred income taxes		(47.1	)		(30.7	)		(26.8	)		(104.6	)
Other		(1.1	)		6.2			4.0			9.1
TOTAL		74.1			119.7			107.2			301.0
Changes In:
Accounts receivables		19.8			(47.5	)		13.9			(13.8	)
Inventories		(22.5	)		(9.4	)		(4.0	)		(35.9	)
Prepaid expenses		(4.4	)		(1.8	)		(1.2	)		(7.4	)
Accounts payable		(3.0	)		(6.1	)		(12.0	)		(21.1	)
Income tax receivable (payable)		14.6			8.3			(3.3	)		19.6
Accrued Interest		70.0			(70.6	)		64.9			64.3
Other		(93.1	)		33.0			6.4			(53.7	)
Cash From Operations	$	55.5		$	25.6		$	171.9		$	253.0
Capital expenditures		(53.9	)		(52.1	)		(40.9	)		(146.9	)
Free Cash Flow	$	1.6		$	(26.5	)	$	131.0		$	106.1
Acquisitions, net of cash acquired		(2.4	)		(6.6	)		(0.8	)		(9.8	)
Proceeds from sales of investments		3.4			2.9			9.8			16.1
Purchases of investments		(1.8	)		(2.0	)		(9.5	)		(13.3	)
Loss on bond repurchase		—			—			(0.7	)		(0.7	)
Proceeds from sale of property and equipment		—			—			0.5			0.5
Repurchase of common shares		(0.6	)		(0.5	)		(0.4	)		(1.5	)
Add back: cash paid for interest		58.9			198.2			59.8			316.9
Effect of exchange rates on cash		0.7			(0.4	)		2.4			2.7
Unlevered Free Cash Flow (1)	$	59.8		$	165.1		$	192.1		$	417.0

(1) Free cash flow (FCF) that does not take into account the interest payments required on outstanding debt. Commonly used by companies that are highly leveraged to show how assets perform before interest.

BIOMET, INC.

Other Financial Information

GAAP Operating Cash Flow Reconciled to Free Cash Flow & Unlevered Free Cash Flow

(in millions, unaudited)

	Fiscal 2009
	Three Months Ended August 31, 2008			Three Months Ended November 30, 2008			Three Months Ended February 28, 2009			Nine Months Ended February 28, 2009
Net loss	$	(59.9	)	$	(39.7	)	$	(478.7	)	$	(578.3	)
Adjustments:
Depreciation and amortization		131.4			130.0			134.8			396.2
Amortization of deferred financing costs		2.8			2.9			2.8			8.5
Goodwill and intangible assets impairment charge		—			—			448.5			448.5
Stock based compensation expense		7.2			11.6			7.5			26.3
Provision (recovery) for doubtful accounts receivable		5.9			(9.4	)		(3.9	)		(7.4	)
Loss and impairment on investments, net		2.9			3.6			7.1			13.6
Provision (recovery) for inventory obsolescence		8.2			(7.8	)		0.5			0.9
Deferred income taxes		(31.6	)		(38.1	)		(76.3	)		(146.0	)
Other		0.7			(0.8	)		4.0			3.9
TOTAL		67.6			52.3			46.3			166.2
Changes In:
Accounts receivables		(1.4	)		(39.1	)		(4.1	)		(44.6	)
Inventories		(26.6	)		1.1			2.8			(22.7	)
Prepaid expenses		6.0			(8.6	)		3.7			1.1
Accounts payable		(17.7	)		11.0			(0.2	)		(6.9	)
Income tax receivable (payable)		(8.2	)		2.5			58.1			52.4
Accrued Interest		68.8			(69.6	)		60.1			59.3
Other		(22.6	)		32.1			(17.9	)		(8.4	)
Cash From Operations	$	65.9		$	(18.3	)	$	148.8		$	196.4
Capital expenditures		(41.0	)		(51.9	)		(34.5	)		(127.4	)
Free Cash Flow	$	24.9		$	(70.2	)	$	114.3		$	69.0
Acquisitions, net of cash acquired		(2.0	)		(0.2	)		(7.3	)		(9.5	)
Capital contributions		0.2			1.7			1.8			3.7
Repurchase of common shares		(0.2	)		(0.4	)		(0.1	)		(0.7	)
Add back: cash paid for interest		69.1			274.6			66.6			343.7
Effect of exchange rates on cash		(1.0	)		(6.8	)		(3.6	)		(11.4	)
Unlevered Free Cash Flow (1)	$	91.0		$	198.7		$	171.7		$	394.8

(1) Free cash flow (FCF) that does not take into account the interest payments required on outstanding debt. Commonly used by companies that are highly leveraged to show how assets perform before interest.

BIOMET, INC.

Other Financial Information

Gross Profit, as reported to Gross Profit, as adjusted

(in millions, unaudited)

	Three Months Ended February 28, 2010			Three Months Ended February 28, 2009
Gross profit, as reported	$	475.1		$	428.9
Purchase accounting depreciation		4.4			4.4
Share-based payment		0.3			0.6
Litigation settlements and reserves and other legal fees		(5.8	)		0.7
Operational restructuring		1.0			0.9
Consulting expenses related to operational improvement initiatives, and other related costs		1.9			2.5
Gross profit, as adjusted*	$	476.9		$	438.0
Net sales	$	669.8		$	615.0
Gross profit margin, as reported		70.9	%		69.7	%
Gross profit margin, as adjusted*		71.2	%		71.2	%

* See Non-GAAP Financial Measures Disclosure Above

BIOMET, INC.

Other Financial Information

Gross Profit, as reported to Gross Profit, as adjusted

(in millions, unaudited)

	Nine Months Ended February 28, 2010			Nine Months Ended February 28, 2009
Gross profit, as reported	$	1,401.9		$	1,302.3
Purchase accounting depreciation		13.3			13.4
Share-based payment		1.2			2.1
Litigation settlements and reserves and other legal fees		(6.9	)		6.0
Operational restructuring		10.8			1.2
Consulting expenses related to operational improvement initiatives, and other related costs		7.7			5.9
Gross profit, as adjusted*	$	1,420.3		$	1,325.0
Net sales	$	1,995.5		$	1,864.8
Gross profit margin, as reported		70.3	%		69.8	%
Gross profit margin, as adjusted*		71.2	%		71.1	%

* See Non-GAAP Financial Measures Disclosure Above

BIOMET, INC.

Other Financial Information

Selling, General and Administrative Expense, as reported to Selling, General and Administrative Expense, as adjusted

(in millions, unaudited)

	Three Months Ended February 28, 2010			Three Months Ended February 28, 2009
Selling, general and administrative expense, as reported	$	256.1		$	244.0
Share-based payment		(3.9	)		(6.1	)
Distributor agreements		—			—
Litigation settlements and reserves and other legal fees		(8.7	)		(3.9	)
Operational restructuring		(0.5	)		(4.2	)
Consulting expenses related to operational improvement initiatives, and other related costs		(0.6	)		(1.1	)
Sponsor fee		(2.6	)		(2.2	)
Other		—			(2.5	)
Selling, general and administrative expense, as adjusted*	$	239.8		$	224.0
Net sales	$	669.8		$	615.0
SG&A as a percent of sales, as reported		38.2	%		39.7	%
SG&A as a percent of sales, as adjusted*		35.8	%		36.4	%

* See Non-GAAP Financial Measures Disclosure Above

BIOMET, INC.

Other Financial Information

Selling, General and Administrative Expense, as reported to Selling, General and Administrative Expense, as adjusted

(in millions, unaudited)

	Nine Months Ended February 28, 2010			Nine Months Ended February 28, 2009
Selling, general and administrative expense, as reported	$	769.5		$	752.2
Share-based payment		(11.3	)		(21.1	)
Distributor agreements		—			(2.0	)
Litigation settlements and reserves and other legal fees		(16.1	)		(13.6	)
Operational restructuring		(5.2	)		(8.7	)
Consulting expenses related to operational improvement initiatives, and		(3.4	)		(6.7	)
other related costs
Sponsor fee		(7.5	)		(6.7	)
Other		—			(4.1	)
Selling, general and administrative expense, as adjusted*	$	726.0		$	689.3
Net sales	$	1,995.5		$	1,864.8
SG&A as a percent of sales, as reported		38.6	%		40.3	%
SG&A as a percent of sales, as adjusted*		36.4	%		37.0	%

* See Non-GAAP Financial Measures Disclosure Above

BIOMET, INC.

Other Financial Information

Research and Development Expense, as reported to Research and Development Expense, as adjusted

(in millions, unaudited)

	Three Months Ended February 28, 2010			Three Months Ended February 28, 2009
Research and development expense, as reported	$	26.6		$	20.0
Share-based payment		(0.6	)		(0.8	)
Litigation settlements and reserves and other legal fees		—			0.9
Operational restructuring		(0.1	)		—
Research and development expense, as adjusted*	$	25.9		$	20.1
Net sales	$	669.8		$	615.0
R&D as a percent of sales, as reported		4.0	%		3.3	%
R&D as a percent of sales, as adjusted*		3.9	%		3.3	%

* See Non-GAAP Financial Measures Disclosure Above

BIOMET, INC.

Other Financial Information

Research and Development Expense, as reported to Research and Development Expense, as adjusted

(in millions, unaudited)

	Nine Months Ended February 28, 2010			Nine Months Ended February 28, 2009
Research and development expense, as reported	$	76.7		$	66.9
Share-based payment		(1.8	)		(3.1	)
Litigation settlements and reserves and other legal fees		1.1			0.9
Operational restructuring		(0.3	)		—
Research and development expense, as adjusted*	$	75.7		$	64.7
Net sales	$	1,995.5		$	1,864.8
R&D as a percent of sales, as reported		3.8	%		3.6	%
R&D as a percent of sales, as adjusted*		3.8	%		3.5	%

* See Non-GAAP Financial Measures Disclosure Above